Lowe's, Target Miss...
Health Care: Drugs
Keryx Biopharmaceuticals Inc. (KERX: NASDAQ)
$8.16 0.11 | 1.37%
05/22/13 - 11:54 AM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 8.05 |
| 52 Week High | 9.98 |
| 52 Week Low | 1.55 |
| Avg. Daily Vol. (Mil) | 2.92 |
| Beta (3 year) | 3.43 |
| Share Related Items | |
| Mkt Cap (Mil) | 657.83 |
| Shares Out (Mil) | 81.72 |
| Float (Mil) | 71.41 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 10.00 |
| Current Ratio | 10.30 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 93.98 |
| Price/Book | 7.84 |
| Price/Cash Flow | -36.00 |
| Per Share Data | |
| Earnings | -0.23 |
| Sales | 0.09 |
| Book Value | 1.03 |
| Cash Flow | -0.22 |
| Business Summary | |
|---|---|
| Keryx Biopharmaceuticals, Inc is a biopharmaceutical company engaged in the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. | |
| General Information | |
| 750 Lexington Avenue
New York, NY 10022 |
|
| www.keryx.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 25 | |
| CEO: Ron Bentsur | |
| Short Interest | |
| Current Month (Mil) | 16.86 |
| Previous Month (Mil) | 15.32 |
| Short Interest Ratio (Days) | 6.40 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -19.80 |
| Return on Investments | -21.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with KERX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserBio
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- User1st Time out
Latest KERX Headlines from TheStreet
- Why Keryx is Lagging But Acadia is Zooming (Hint: It's About NCE) 05.21.13 | 10:05 am
- Rockwell Medical Run-Up Trade Follows Financing 05.21.13 | 08:05 am
- Short Interest Increases 10% For KERX 05.10.13 | 04:05 pm
- Keryx Biopharmaceuticals Inc. (KERX): Today's Featured Health Care Winner 04.22.13 | 05:04 pm
- Today's Drugs Industry Featured Laggard: Keryx Biopharmaceuticals Inc. (KERX) 04.11.13 | 05:04 pm
- Bears Eat Herbalife, JC Penney - Bulls Find Keryx
04.09.13 | 12:04 pm - Keryx Biopharmaceuticals Inc. (KERX): Health Care's Highlighted Dud Of The Day 03.26.13 | 05:03 pm
- Keryx CEO vs. A Short Seller: Zerenex Patent Debate 03.13.13 | 07:03 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan 03.08.13 | 07:03 pm
- Why Expect More Price Swings From These 4 Biotechs 02.28.13 | 11:02 am
Press Releases for KERX
- Keryx Biopharmaceuticals, Inc. To Host Conference Call On First Quarter 2013 Financial Results - PR Newswire 05.06.13 | 04:05 pm
- SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Keryx Biopharmaceuticals, Inc. Of Class Action Lawsuit And The Deadline Of April 2, 2013 To Seek A Lead Plaintiff Position - Business Wire 03.25.13 | 08:03 am
- SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Keryx Biopharmaceuticals, Inc. Of Class Action Lawsuit And The Deadline Of April 2, 2013 To Seek A Lead Plaintiff Position - PR Newswire 03.19.13 | 06:03 pm
- SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Keryx Biopharmaceuticals, Inc. Of Class Action Lawsuit And The Deadline Of April 2, 2013 To Seek A Lead Plaintiff Position - Business Wire 03.18.13 | 05:03 pm
- Keryx Biopharmaceuticals To Present At The 25th Annual ROTH Conference - PR Newswire 03.14.13 | 08:03 am
- Keryx Biopharmaceuticals Announces Appointment Of Amit Sharma, M.D. As Vice President, Medical Affairs - PR Newswire 03.13.13 | 08:03 am
- Keryx Biopharmaceuticals, Inc. To Host Conference Call On Fourth Quarter And Year-End 2012 Financial Results - PR Newswire 03.11.13 | 08:03 am
- Keryx Biopharmaceuticals To Present At The Citigroup 2013 Global Healthcare Conference - PR Newswire 02.22.13 | 08:02 am
- Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact The Firm - PR Newswire 02.08.13 | 09:02 pm
- Harwood Feffer LLP Announces Investigation Of Keryx Biopharmaceuticals, Inc. - PR Newswire 02.08.13 | 12:02 pm
Partner Headlines for KERX
- Zerenex Phase III Data Imminent; Odds Still High For Keryx To Succeed With This Drug - Seeking Alpha 01.22.13 | 09:01 am
- Dawson James Securities Reiterates Market Outperform Rating, $4 PT on Keryx Biopharmaceuticals - Benzinga 11.28.12 | 09:11 am
- Healthcare Biz Roundup: Keryx Jumps Without CAUSE, Teva Not A MONOPOLIST - Wall St. Cheat Sheet 07.04.12 | 08:07 am
- Zacks' Voice of the People highlights opportunities with Starbucks, Realty Income, Keryx Biopharma, Bon-Ton Stores and Orexigen Therapeutics - Press Releases - Zacks 04.12.12 | 09:04 am
- 2 Biotech Stocks To Consider Now, 1 To Avoid - Seeking Alpha 04.10.12 | 09:04 am
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- VIX - Options Volatility Sonar: Friday Recap - Seeking Alpha 03.16.12 | 05:03 pm
- Morning Social Media Outlook for Tuesday Mar 6 (SHFL, HAR, PCX, NTRI) - Benzinga 03.06.12 | 09:03 am
- FDA Approval Practically A Done Deal For Keryx And AEterna Zentaris - Seeking Alpha 03.02.12 | 05:03 pm
- 3 Boring Dividend Stocks You Will Grow To Love - Seeking Alpha 02.26.12 | 07:02 am
